Omega Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Omega Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q2 2024.
  • Omega Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$16.3M, a 45.1% increase year-over-year.
  • Omega Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$78.9M, a 29.3% increase year-over-year.
  • Omega Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$97.4M, a 5.13% increase from 2022.
  • Omega Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$103M, a 50.4% decline from 2021.
  • Omega Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$68.3M, a 132% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$78.9M -$16.3M +$13.4M +45.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$92.3M -$20.1M +$5.15M +20.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-06
Q4 2023 -$97.4M -$20.2M +$10.6M +34.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$108M -$22.2M +$3.55M +13.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$112M -$29.7M -$3.78M -14.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$108M -$25.3M -$5.12M -25.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-06
Q4 2022 -$103M -$30.8M -$9.97M -47.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$92.7M -$25.8M -$7.27M -39.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$85.5M -$25.9M -$10.5M -68.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$75M -$20.2M -$6.68M -49.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$68.3M -$20.9M -$11.4M -120% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-01
Q3 2021 -$56.9M -$18.5M -$10.3M -125% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$46.6M -$15.4M -$9.09M -144% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$37.5M -$13.5M -$8.07M -149% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$29.4M -$9.47M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$8.24M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$6.32M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$5.42M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.